Patents by Inventor Kiran Kumar Vangara

Kiran Kumar Vangara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SELF-EMULSIFYING CANNABIDIOL FORMULATIONS
    Publication number: 20240099971
    Abstract: The present invention is directed to a self-emulsifying cannabidiol composition containing one or more surfactants. The present invention is further directed to a method of treating a disease comprising administering a composition of the present invention to a subject in need thereof. The present invention is further directed to a method of treating withdrawal symptoms.
    Type: Application
    Filed: December 8, 2023
    Publication date: March 28, 2024
    Inventors: Kiran Kumar Vangara, Thrimoorthy Potta, Venkat Goskonda
  • Stable cannabinoid formulations
    Patent number: 11911361
    Abstract: The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: February 27, 2024
    Assignee: RADIUS PHARMACEUTICALS, INC.
    Inventors: Kiran Kumar Vangara, Huaguang Li, Ningxin Yan, Hung Q. Nguyen, Venkat R. Goskonda
  • Self-emulsifying cannabidiol formulations
    Patent number: 11857678
    Abstract: The present invention is directed to a self-emulsifying cannabidiol composition containing one or more surfactants. The present invention is further directed to a method of treating a disease comprising administering a composition of the present invention to a subject in need thereof. The present invention is further directed to a method of treating withdrawal symptoms.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: January 2, 2024
    Assignee: Benuvia Operations, LLC
    Inventors: Kiran Kumar Vangara, Thrimoorthy Potta, Venkat Goskonda
  • 3Alpha-OH-5Beta-Pregnan-20-One Compositions and Methods for Treating Central Nervous System Disorders
    Publication number: 20230321116
    Abstract: Disclosed are methods and oral compositions for treating CNS disorders. An embodiment of the invention comprises orally administering a 3?-OH-5?-pregnan-20-one containing composition to a subject having a CNS disorder. The composition preferably exhibits a fast release rate of the 3?-OH-5?-pregnan-20-one. The current compositions may provide desired serum levels of 3?-OH-5?-pregnan-20-one to effectively treat CNS disorders. The oral compositions and methods disclosed herein may be administered to a subject in need of CNS disorder therapy, to deliver therapeutically effective amounts of 3?-OH-5?-pregnan-20-one for treating CNS disorders.
    Type: Application
    Filed: March 28, 2022
    Publication date: October 12, 2023
    Applicant: Lipocine Inc.
    Inventors: Kilyoung Kim, Kongnara Papangkorn, Kiran Kumar Vangara, Nachiappan Chidambaram, Mahesh V. Patel
  • Compositions and Methods for Treating CNS Disorders
    Publication number: 20220354867
    Abstract: The present disclosure is drawn to compositions and methods for treating CNS disorders. In one embodiment, an oral pharmaceutical composition can comprise a therapeutically effective amount of pregn-4-ene-3,20-dione; and a pharmaceutically acceptable carrier that provides formation of either 3?-OH-5?-pregnan-20-one, or 3?-OH-5?-pregnan-20-one, or both in an amount sufficient to treat a CNS disorder when orally administered to a subject. In another embodiment, a method of treating a CNS disorder can comprise orally administering to a subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of GABA receptor binding pregn-4-ene-3,20-dione metabolites that is sufficient to treat the CNS disorder.
    Type: Application
    Filed: May 10, 2022
    Publication date: November 10, 2022
    Applicant: Lipocine Inc.
    Inventors: Mahesh V. Patel, Nachiappan Chidambaram, Kilyoung Kim, Kongnara Papangkorn, Benjamin J. Bruno, Kiran Kumar Vangara
  • Compositions and methods for treating CNS disorders
    Patent number: 11478485
    Abstract: The present disclosure is drawn to compositions and methods for treating CNS disorders. In one embodiment, an oral pharmaceutical composition can comprise a therapeutically effective amount of pregn-4-ene-3,20-dione; and a pharmaceutically acceptable carrier that provides formation of either 3?-OH-5?-pregnan-20-one, or 3?-OH-5?-pregnan-20-one, or both in an amount sufficient to treat a CNS disorder when orally administered to a subject. In another embodiment, a method of treating a CNS disorder can comprise orally administering to a subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of GABA receptor binding pregn-4-ene-3,20-dione metabolites that is sufficient to treat the CNS disorder.
    Type: Grant
    Filed: May 10, 2022
    Date of Patent: October 25, 2022
    Inventors: Mahesh V. Patel, Nachiappan Chidambaram, Kilyoung Kim, Kongnara Papangkorn, Benjamin J. Bruno, Kiran Kumar Vangara
  • STABLE CANNABINOID FORMULATIONS
    Publication number: 20220280446
    Abstract: The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.
    Type: Application
    Filed: February 18, 2022
    Publication date: September 8, 2022
    Applicant: RADIUS PHARMACEUTICALS, INC.
    Inventors: Kiran Kumar Vangara, Huaguang Li, Ningxin Yan, Hung Q. Nguyen, Venkat R. Goskonda
  • STABLE CANNABINOID FORMULATIONS
    Publication number: 20220184215
    Abstract: The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.
    Type: Application
    Filed: December 22, 2021
    Publication date: June 16, 2022
    Applicant: RADIUS PHARMACEUTICALS, INC.
    Inventors: Kiran Kumar VANGARA, Huaguang LI, Ningxin YAN, Hung Q. Nguyen, Venkat R. GOSKONDA
  • Compositions and methods for treating central nervous system disorders
    Patent number: 11337987
    Abstract: The present disclosure is drawn to compositions and methods for treating CNS disorders. In one embodiment, an oral pharmaceutical composition can comprise a therapeutically effective amount of pregn-4-ene-3,20-dione; and a pharmaceutically acceptable carrier that provides formation of either 3?-OH-5?-pregnan-20-one, or 3?-OH-5?-pregnan-20-one, or both in an amount sufficient to treat a CNS disorder when orally administered to a subject. In another embodiment, a method of treating a CNS disorder can comprise orally administering to a subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of GABA receptor binding pregn-4-ene-3,20-dione metabolites that is sufficient to treat the CNS disorder.
    Type: Grant
    Filed: May 7, 2021
    Date of Patent: May 24, 2022
    Inventors: Mahesh V. Patel, Nachiappan Chidambaram, Kilyoung Kim, Kongnara Papangkorn, Benjamin J. Bruno, Kiran Kumar Vangara
  • Stable cannabinoid formulations
    Patent number: 11331279
    Abstract: The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: May 17, 2022
    Assignee: RADIUS PHARMACEUTICALS, INC.
    Inventors: Kiran Kumar Vangara, Huaguang Li, Ningxin Yan, Hung Q. Nguyen, Venkat R. Goskonda
  • STABLE CANNABINOID FORMULATIONS
    Publication number: 20220125932
    Abstract: The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.
    Type: Application
    Filed: November 5, 2021
    Publication date: April 28, 2022
    Applicant: RADIUS PHARMACEUTICALS INC.
    Inventors: Kiran Kumar VANGARA, Huaguang Li, Ningxin Yan, Hung Q. Nguyen, Venkat R. Goskonda
  • STABLE CANNABINOID FORMULATIONS
    Publication number: 20220054450
    Abstract: The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.
    Type: Application
    Filed: November 5, 2021
    Publication date: February 24, 2022
    Applicant: RADIUS PHARMACEUTICALS, INC.
    Inventors: Kiran Kumar Vangara, Huaguang Li, Ningxin Yan, Hung Q. Nguyen, Venkat R. Goskonda
  • Stable cannabinoid formulations
    Patent number: 11224660
    Abstract: The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: January 18, 2022
    Assignee: RADIUS PHARMACEUTICALS, INC.
    Inventors: Kiran Kumar Vangara, Huaguang Li, Ningxin Yan, Hung Q. Nguyen, Venkat R. Goskonda
  • STABLE CANNABINOID FORMULATIONS
    Publication number: 20210330797
    Abstract: The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.
    Type: Application
    Filed: July 6, 2021
    Publication date: October 28, 2021
    Applicant: RADIUS PHARMACEUTICALS, INC.
    Inventors: Kiran Kumar Vangara, Huaguang Li, Ningxin Yan, Hung Q. Nguyen, Venkat R. Goskonda
  • SELF-EMULSIFYING CANNABIDIOL FORMULATIONS
    Publication number: 20200360286
    Abstract: The present invention is directed to a self-emulsifying cannabidiol composition containing one or more surfactants. The present invention is further directed to a method of treating a disease comprising administering a composition of the present invention to a subject in need thereof. The present invention is further directed to a method of treating withdrawal symptoms.
    Type: Application
    Filed: May 14, 2020
    Publication date: November 19, 2020
    Inventors: Kiran Kumar Vangara, Thrimoorthy Potta, Venkat Goskonda
  • Sublingual ondansetron spray
    Patent number: 10172833
    Abstract: The invention is directed to sublingual spray formulations containing ondansetron, a pharmaceutically acceptable salt thereof, and a solvent consisting of ethanol and glycerin, suitable for administration to humans, and methods for treatment with sublingual formulations.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: January 8, 2019
    Assignee: INSYS DEVELOPMENT COMPANY, INC.
    Inventors: Kiran Kumar Vangara, Chandeshwari Shivani Chilampalli, Venkat R. Goskonda
  • STABLE CANNABINOID FORMULATIONS
    Publication number: 20180028489
    Abstract: The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.
    Type: Application
    Filed: September 22, 2017
    Publication date: February 1, 2018
    Inventors: Kiran Kumar Vangara, Huaguang Li, Ningxin Yan, Hung Q. Nguyen, Venkat R. Goskonda
  • Diclofenac sublingual spray
    Patent number: 9855234
    Abstract: The present invention is directed to diclofenac sublingual spray formulations. The present invention is also directed to methods for treating pain and inflammation by administering the formulations of the present invention to patients in need thereof.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: January 2, 2018
    Assignee: INSYS DEVELOPMENT COMPANY, INC.
    Inventors: Kiran Kumar Vangara, Daniela Bockenstedt, Ningxin Yan, Rajesh Pandya, Venkat R. Goskonda
  • STABLE CANNABINOID FORMULATIONS
    Publication number: 20170224634
    Abstract: The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.
    Type: Application
    Filed: April 27, 2017
    Publication date: August 10, 2017
    Inventors: Kiran Kumar Vangara, Huaguang Li, Ningxin Yan, Hung Q. Nguyen, Venkat R. Goskonda
  • ONDANSETRON SUBLINGUAL SPRAY FORMULATION
    Publication number: 20170105970
    Abstract: The invention is directed to sublingual spray formulations containing ondansetron or a pharmaceutically acceptable salt thereof and water. The invention is further directed to methods for treating or preventing nausea and emesis associated with cancer treatments by administering sublingual spray formulations containing ondansetron or a pharmaceutically acceptable salt thereof to a patient in need thereof.
    Type: Application
    Filed: December 27, 2016
    Publication date: April 20, 2017
    Inventors: Kiran Kumar Vangara, Chandeshwari Shivani Chilampalli, Venkat R. Goskonda